Pharmacologic effects on cardiac remodeling
| Autor: | Norman Sharpe |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Adrenergic beta-Antagonists Myocardial Infarction Angiotensin-Converting Enzyme Inhibitors Renin-Angiotensin System Nitroglycerin Ventricular Dysfunction Left Physiology (medical) Internal medicine medicine Humans Thrombolytic Therapy Myocardial infarction Ventricular remodeling Carvedilol Heart Failure Ventricular Remodeling business.industry Vascular surgery medicine.disease Cardiac surgery Clinical research Heart failure cardiovascular system Emergency Medicine Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Current Heart Failure Reports. 1:9-13 |
| ISSN: | 1546-9549 1546-9530 |
| DOI: | 10.1007/s11897-004-0011-x |
| Popis: | Clinical research during the past several decades has shown the importance of cardiac remodeling as a basic mechanism in the progression of heart failure. Changes in cardiac remodeling have high concordance with long-term clinical outcomes. Cardiac remodeling should be regarded as a primary target for treatment and also can serve as a reliable surrogate for clinical outcomes. Neurohormonal blockade with combination treatments that inhibit the renin-angiotensin-aldosterone and sympathetic systems has proven effective in improving cardiac remodeling and clinical outcomes. Such treatment should be standard therapy for patients with left ventricular dysfunction after myocardial infarction and patients with chronic heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink